Forward Looking NMIBC Treatment Advancements and Needs in 2024
In this final episode, panelists conclude with reflections on the significant progress made in treating NMIBC over the past decade, particularly in the last 5 years. Looking ahead to 2024, experts in urology express excitement about investigational treatments (ie, cretostimogene grenadenorepvec and UGN 102), the potential for personalized medicine, emphasizing the need to understand molecular characteristics of the disease for better treatment customization. The session also highlights the importance of balancing quality of life with effective treatment strategies, and the prospect of utilizing emerging therapies early in the disease process.
EP: 1.Overview of Non-Muscle Invasive Bladder Cancer (NMIBC)
EP: 2.Appropriate Risk Stratification Intermediate and high-risk Risk Classification
EP: 3.Adapting Urology Practices in the Face of BCG Shortages
EP: 4.Initial Treatment Selection for NMIBC in the Era of BCG Shortage
EP: 5.Strategies for the Management of Recurrent Low-Grade Bladder Tumors
EP: 6.Navigating Treatment Options for Elderly Patients with High-Risk NMIBC
EP: 7.Investigational Novel Strategies in High-Risk BCG-Unresponsive NMIBC
EP: 8.Review of Cretostimogene Grenadenorepvec (CG) Clinical Trials in High-risk BCG-unresponsive NMIBC
EP: 9.Emerging Treatments High-Risk BCG-Unresponsive NMIBC setting
EP: 10.Treatment Strategies for BCG-Unresponsive NMIBC
EP: 11.Novel Approaches and Recent Trial Updates in Intermediate-risk NMIBC
EP: 12.Forward Looking NMIBC Treatment Advancements and Needs in 2024
This is a synopsis of the Viewpoints video series featuring moderator, Sam S. Chang, MD, MBA, from Vanderbilt University School of Medicine, and panelists Gary Steinberg, MD, FACS, from Rush University Medical Center, Mark Tyson, MD, of Mayo Clinic Phoenix, Roger Li, MD, from Moffitt Cancer Center, and Sandip M. Prasad, MD, MPhil, of Morristown Medical Center.
Episode 12 concludes with reflections on the remarkable progress in treating non-muscle invasive bladder cancer (NMIBC) over the past decade, especially in the last five years. The experts look ahead to 2024 with enthusiasm about new treatments and the potential for personalized medicine. They emphasize the need to understand the molecular characteristics of NMIBC for improved treatment customization. This session also highlights the importance of balancing quality of life with effective treatment strategies and the prospect of utilizing emerging therapies early in the disease process. Dr. Gary Steinberg expresses excitement about creative stem and gene therapy, particularly cretostimogene grenadenorepvec combined with checkpoint inhibitors, considering their novel mechanism of action. He also mentions the FGFR3 inhibitors, highlighting their potential in personalized targeted therapy, despite some systemic side effects. Dr. Roger Lee focuses on the molecular understanding of NMIBC, stressing the value of analyzing tumor and urine samples to understand disease dynamics and develop personalized treatment approaches. The panel discusses the challenges in treating NMIBC, including the need for cystectomies and intensive intravascular treatments. They advocate for individualized care and emphasize understanding each patient's unique disease characteristics. Dr. Sandip M. Prasad speaks about the quality of life aspects and the financial burden of bladder cancer treatment. He suggests de-intensifying treatments for certain patient groups and considering non-surgical therapeutic approaches. The experts also discuss the exciting prospects of intravascular antibody-drug conjugates (ADCs) and the impressive response rates from studies like EV-302(of enfortumab vedotin). They highlight the importance of molecular characterization of tumors for selecting appropriate therapies, which they see as the next frontier in NMIBC treatment.
The session concludes with an acknowledgment of the significant evolution in NMIBC treatment options, comparing it to the advancements seen in prostate cancer treatment. The panelists express optimism about the future of bladder cancer care, underscoring the need to understand patient-specific risks better and utilize emerging therapies effectively.
*Video synopsis is AI-generated and reviewed by Urology Times® editorial staff.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
